RBC Capital Reiterates Outperform on Arrowhead Pharma, Maintains $100 Price Target

Benzinga Newsdesk www.benzinga.com Negative 79.8%

Neg 79.8% Neu 0% Pos 0%

RBC Capital analyst Luca Issi reiterates Arrowhead Pharma (NASDAQ:ARWR) with a Outperform and maintains $100 price target.